Selexis CHO Cells in Suspension-1

Archives 2021

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

 

NOVEMBER 1, 2021
3 min read

Meet Selexis During Key Industry Conferences to Learn About the Latest Innovations in Cell Line Development

Geneva, Switzerland, November 1, 2021Selexis SA, a JSR Life Sciences company, today announced that business and...

Read More
JUNE 29, 2021
3 min read

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

Geneva, Switzerland, and Durham, NC – June 29, 2021Selexis SA and KBI Biopharma (KBI), both JSR Life Sciences...

Read More
JUNE 1, 2021
2 min read

Selexis Appoints Roland Hoffmann-Hecht, PhD, as Chief Business Officer

Business Development Executive in Biologics Drug Development and Manufacturing Brings More than 25 Years of...

Read More
MAY 27, 2021
3 min read

Great Place to Work® Designates Selexis as One of the Best Workplaces™ Switzerland for Fourth Straight Year

Geneva, Switzerland, May 27, 2021  Selexis SA, a JSR Life Sciences company, announced today that Great Place to Work® ...

Read More
MARCH 24, 2021
3 min read

Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service...

Read More
MARCH 18, 2021
3 min read

SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vaccine Program

Geneva, Switzerland, March 18, 2021  Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company...

Read More
MARCH 16, 2021
2 min read

Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

Pandion will leverage Selexis’ proprietary technology platform to advance an antibody targeting autoimmune and...

Read More